SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company
engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it
will report fourth quarter and full year 2018 financial results after the market close on Monday, March 25, 2019. Management
will host a conference call and webcast to review the results and provide an operational update.
Conference Call and Webcast Details:
Monday, March 25th @ 5:00 p.m. EDT / 2:00
p.m. PDT
Domestic: (844) 358-9116
International: (209) 905-5951
Conference ID: 1849119
Webcast: http://investors.atyrpharma.com/events-and-webcasts
About aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on
novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology,
the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential
pipeline of protein compositions derived from 20 tRNA synthetase genes. aTyr is focused on the therapeutic translation of the
Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a
clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in
interstitial lung diseases and other immune-mediated diseases. For more information, please visit http://www.atyrpharma.com.
